Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ovid Therapeutics Inc OVID

Healthcare Biotechnology
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other... see more

Recent & Breaking News (NDAQ:OVID)

Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference

GlobeNewswire September 11, 2020

Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock

GlobeNewswire August 25, 2020

Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome

Business Wire August 25, 2020

Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire August 10, 2020

Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020

GlobeNewswire August 5, 2020

Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome

GlobeNewswire July 23, 2020

Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe

GlobeNewswire July 13, 2020

Ovid Therapeutics Added to Russell 2000® and Russell 3000® Indexes

GlobeNewswire June 29, 2020

Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome

GlobeNewswire June 19, 2020

Ovid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological Diseases

GlobeNewswire June 11, 2020

Ovid Therapeutics Announces Multiple Presentations on the 2020 American Academy of Neurology Science Highlights Platform

GlobeNewswire June 8, 2020

Ovid Therapeutics Launches Pipeline Teach-In Webinar Series

GlobeNewswire June 4, 2020

Ovid Therapeutics Announces Participation in the 2020 RBC Capital Markets Virtual Global Healthcare Conference

GlobeNewswire May 12, 2020

Ovid Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire May 7, 2020

Ovid Therapeutics Announces Positive Topline Results from the Phase 2 ROCKET Trial of OV101 for the Treatment of Fragile X Syndrome

GlobeNewswire May 7, 2020

Ovid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome

GlobeNewswire March 30, 2020

Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020

GlobeNewswire March 11, 2020

Ovid Therapeutics Announces Multiple Presentations at the American Academy of Neurology 2020 Annual Meeting

GlobeNewswire March 5, 2020

Ovid Therapeutics Names Alexander Kolevzon, M.D., to Scientific Advisory Board

GlobeNewswire March 2, 2020

Ovid Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference

GlobeNewswire February 25, 2020